Portugal - English - HMA (Heads of Medicines Agencies)

pfizer limited - feline leukaemia virus 8.1 log2 - suspension for injection - cats non food - feline leukaemia virus

Romania - English - HMA (Heads of Medicines Agencies)

pfizer limited - feline leukaemia virus 8.1 log2 - suspension for injection - cats non food - feline leukaemia virus

Slovenia - English - HMA (Heads of Medicines Agencies)

pfizer limited - feline leukaemia virus 8.1 log2 - suspension for injection - cats non food - feline leukaemia virus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

virbac (australia) pty ltd - feline leukaemia - unknown - feline leukaemia vaccine active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - feline leukaemia virus - inactivated - vaccine or antisera - feline leukaemia virus - inactivated vaccine-viral active 0.0 u - immunotherapy

New Zealand - English - Ministry for Primary Industries

virbac new zealand limited - feline leukaemia virus (inactivated) - feline leukaemia virus (inactivated) 0 vaccine - vaccine

Ireland - English - HPRA (Health Products Regulatory Authority)

virbac s.a. - feline leukemia virus envelope antigen p45 - suspension for injection - %v/v - feline leukaemia virus vaccine - feline - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

virbac s.a. - purified p45 felv-envelope antigen - inactivated viral vaccines, feline leukaemia virus, immunologicals for felidae, - cats - active immunisation of cats from eight weeks of age against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease.

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - inactivated feline leukaemia virus(felv) subtypes a, b and c - suspension for injection - . - feline leukaemia virus - cats - immunological - inactivated vaccine

European Union - English - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - cats - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease.onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.